Fiche du document
23 mars 2022
- doi: 10.53738/REVMED.2022.18.774.522
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.774.522
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35343120
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_260924C7B8AF0
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Therapy Fatness Corpulence Overweight AdiposityCiter ce document
J. Frantz et al., « Le liraglutide a-t-il sa place en psychiatrie ? [Does liraglutide have a place in psychiatry ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.774.522
Métriques
Partage / Export
Résumé
The relative risk of developing MetS is higher in patients with severe mental illness (SMI) than in the general population. Similarly, the risk of developing obesity or type 2 diabetes (T2DM) is also higher in patients with SMI. GLP-1 receptor agonists, such as liraglutide, have been shown to be effective in the treatment of T2DM and, more recently, in obesity or overweight associated with at least one metabolic disease. Their psychiatric adverse effect profiles seem to be reassuring, thus not represent a limitation for prescribing in psy chiatry. We aimed to explore the therapeutic usefulness of liraglutide in patients with psychiatric disorders associated with somatic comorbidities such as obesity, T2DM or MetS.